26th October: 5th Annual Symposium At the Frontiers of Neuroscience: Feelings and Forgetting (Adelaide)

Bionomics & MSD 5th Annual Neuroscience Symposium in October

  • One day program titled The Frontiers of Neuroscience: Feelings & Forgetting
  • In conjunction with the national AusBiotech 2017 conference to be held in Adelaide

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, will again co-host its annual neuroscience symposium with MSD in Adelaide.

The one-day event at the Adelaide Convention Centre on 26 October is entitled The Frontiers of Neuroscience: Feelings & Forgetting featuring world-renowned industry experts. Bionomics and MSD (known as Merck, in the United States and Canada) collaborate to arrange this event.

The annual Bionomics-MSD symposium is in its fifthyear and has demonstrated year on year growth in participation numbers. Last year’s event entitled Frontiers in Neuroscience Research: Memory, Movement and Mood attracted over 200 delegates including researchers, medical personnel, patient support groups, life science analysts and investors. The purpose of this event continues to focus on the importance of finding suitable treatment options for cognitive conditions and keeping participants informed of the latest advances.

The symposium will be opened by Bionomics CEO and Managing Director, Dr Deborah Rathjen and closed by Mr Ben Thorner, Senior Vice President, Business Development & Licensing at MSD.

Some of the key presentations at the symposium this year will be;

  • Professor Steve Williams, IoPPN Kings College London & Maudsley Hospital on MR Neuroimaging to Facilitate the Drug R&D Process -from Mouse to Man
  • Professor Ole Isaacson Professor of Neurology & Neuroscience, Harvard Medical School on Novel Concepts from Human Cell Biology and Genetics for Neurodegenerative Disease Treatments
  • Dr Richard Hargreaves, Corporate Vice President Neuroscience & Imaging, Celgene on Seeing the Problems and Devising Solutions for Neurodegenerative Disease

There will be emphasis upon the treatment of post-traumatic stress disorder (PTSD) at the symposium this year with Professor Malcolm Hopwood, Ramsay Health Care Professor of Psychiatry, University of Melbourne on PTSD: Treatment Opportunities. This presentation will be followed by Dr Sue O’Connor VP Neuroscience from Bionomics who will present an overview on lead drug candidate BNC210 and its potential as a viable anxiolytic – A Novel Therapeutic in Development for PTSD.

 Please find the full program below, registration is free of charge and interested individuals can contact Dr Lauren Nicotra, Senior Associate, Strategic Alliances at symposium@bionomics.com.au to enquire about registration.

5th Annual Symposium – The Frontiers of Neuroscience: Feelings & Forgetting

Adelaide Convention Centre, North Terrace, Adelaide, Thursday 26 October 2017

 

Time Speaker Topic

 

SESSION 1:
9.15 Dr Deborah Rathjen

CEO & Managing Director, Bionomics

 

Welcome
9.30 Professor Steve Williams

IoPPN Kings College London & Maudsley Hospital

 

MR Neuroimaging to Facilitate the Drug R&D Process – from Mouse to Man
10.00 Dr Ann Hayes

The Ann Hayes Consultancy; formerly Director of CNS Therapeutic Research, GlaxoWellcome

 

Multiple Mechanisms for Pain – How Can We Improve the Chances of Success?
10.30        MORNING TEA

 

SESSION 2:
11.00 Dr Richard Hargreaves

Corporate Vice President Neuroscience & Imaging, Celgene

 

Seeing the Problems and Devising Solutions for Neurodegenerative Disease
11.30 Professor Ole Isaacson

Professor of Neurology & Neuroscience,

Harvard Medical School

 

Novel Concepts from Human Cell Biology and Genetics for Neurodegenerative Disease Treatments
12.00 Dr Michael F Egan

Associate Vice President, Clinical Neuroscience, MSD

 

Development of BACE Inhibitors for the Treatment of Alzheimer’s Disease
12.30        LUNCH

 

SESSION 3:
1.30 Dr Paul Coleman

Executive Director, Discovery Chemistry, MSD

 

Discovery of Belsomra, a First-in-Class Orexin Antagonist for the Treatment of Insomnia
2.00 Professor Alexander McFarlane

Director of the Centre for Traumatic Stress Studies, Professor of Psychiatry, University of Adelaide

 

The Importance of a Staging Approach to Psychiatric Illness in Understanding the Role of Biomarkers and Treatment Response
2.30 Professor Paul Rolan

Director of Innovation, University of Adelaide

 

Innovation in Clinical Trial Design
3.00          AFTERNOON TEA

 

SESSION 4:
3.30 Professor Malcolm Hopwood

Ramsay Health Care Professor of Psychiatry,

University of Melbourne

 

PTSD: Treatment Opportunities
4.00 Dr Sue O’Connor

VP Neuroscience, Bionomics

 

BNC210 – A Novel Therapeutic in Development for PTSD
4.30 Mr Ben Thorner

Senior Vice President, Business Development & Licensing, MSD

Close
 

4.45-5.45 NETWORKING WITH DRINKS & CANAPES

 

 

 

 

Home

News & opinion

Member Directory

Events